

SERVICE DE COMPTES RENDUS DE CONGRÈS

Pré CONGRÈS

La sélection des abstracts et des posters les plus prometteurs
du programme, par notre comité scientifique

SABCS 2011 - 6 au 10 décembre 2011

SABCS 2011

San Antonio Breast Cancer Symposium



Un service

PubliClin'

avec le soutien institutionnel de

Roche

COTATIONS

★★★ À NE PAS MANQUER

★★ TRÈS INTÉRESSANT

★ INTÉRESSANT

(Remarque : pour les Poster Sessions seuls sont conservés ici les posters que notre comité scientifique a sélectionnés. La totalité des posters est consultable sur le programme officiel du SABCS 2011).

NOTRE COMITÉ SCIENTIFIQUE

- Pr David Azria
Oncologue radiothérapeute - Montpellier
- Dr Joseph Gligorov
Oncologue médical - Paris
- Dr Anthony Gonçalves
Oncologue médical - Marseille
- Pr Frédérique Penault-Llorca
Pathologiste - Clermont-Ferrand
- Pr Thierry Petit
Oncologue médical - Strasbourg
- Pr Xavier Pivot
Oncologue médical - Besançon
- Dr Rémy Salmon
Chirurgien - Paris
- Pr Laurent Zelek
Oncologue médical - Bobigny

SOMMAIRE

1^{ère} PARTIE

- 7 Le programme au jour le jour et la sélection de notre comité scientifique

2^{ème} PARTIE

- 102 Les sessions cotées ★★★
106 Les sessions cotées ★★

112 VOTRE AGENDA

Ces données sont téléchargeables au format pdf,
sur le site www.publiclin.com*
ou à partir de l'*email* que vous recevrez si vous êtes
abonnés aux services PubliClin' en Oncologie.

Ces données sont disponibles aux formats électroniques :

- ▶ **application iPhone**, à télécharger sur l'Apple Store
- ▶ **version web pour mobiles (Blackberry...)**
consultable en ligne

*Le site www.publiclin.com est réservé aux professionnels de santé.
L'inscription est simple et gratuite : sur le site www.publiclin.com cliquez
sur « le pré-congrès SABCS 2011 » puis sur « m'inscrire » et suivez les
instructions.



SABCS 2011

San Antonio Breast Cancer Symposium

TÉLÉCHARGEZ L'APPLICATION PUBLICLIN PRÉ-CONGRÈS sur votre mobile* :

TOUT LE PRÉ-CONGRÈS
DU SABCS 2011
À PORTÉE DE MAIN !

Quel que soit votre mobile*, des fonctions de recherche indispensables

- ▶ Par jour
- ▶ Par intérêt
- ▶ Par type de session
- ▶ Par auteur, titre, salle...
- ▶ Le plan d'accès aux salles pour chaque session
- ▶ L'intégralité des posters et leur cotation

Et sur iPhone, des fonctions avancées supplémentaires, avec

La gestion de favoris : préparez votre parcours et votre
sélection d'immanquables

Un système d'alerte, qui vous prévient 15 minutes avant le
début des sessions que vous avez sélectionnées

* Tout mobile possédant un accès Internet et un navigateur. L'accès
au Pré-Congrès 2011 sur terminal mobile (y compris iPhone)
nécessite une connexion data pour fonctionner. Si vous vous trouvez
à l'étranger, la consultation des données peut engendrer des
coûts importants en fonction du type de forfait souscrit avec votre
opérateur mobile. Pour utiliser cette application sans passer par
votre forfait opérateur mobile, connectez-vous à un hotspot WIFI (en
général disponible gratuitement sur tous les salons ou congrès).

**TÉLÉCHARGEZ L'APPLICATION PUBLICLIN PRÉ-
CONGRÈS sur votre mobile* :**
TOUT LE PRÉ-CONGRÈS DU SABCS 2011
À PORTÉE DE MAIN !

Pour télécharger l'application iPhone* :

Sur votre Mac ou PC (à partir d'iTunes) :

- ▶ Lancez votre navigateur Internet, tapez <http://www.publiclin.com> : sur la page d'accueil, cliquez sur Téléchargez l'application iPhone Publiclin Pré-congrès. Vous serez automatiquement redirigé sur la page de l'application Publiclin de l'AppleStore dans itunes, il vous suffit de cliquer sur « acheter » (l'application est gratuite).
- ▶ Ou bien dans itunes, cliquez sur « Application », lancez une recherche avec le terme « Publiclin » puis achetez l'application gratuite.
- ▶ Dans les 2 cas ci-dessus, il vous faudra synchroniser votre iPhone pour transférer l'application sur ce dernier.

Directement sur votre iPhone : lancez l'application « App store », sur la toolbar cliquez sur « recherche » et lancez une recherche avec le terme « Publiclin ». Il ne vous reste plus qu'à « acheter » l'application gratuite.

Pour accéder au pré-Congrès du SABCS 2011 sur tous les autres mobiles* :

A partir du navigateur Internet de votre terminal, tapez l'adresse <http://mobile.publiclin.com>

Vous êtes directement sur le site *Publiclin Pré-congrès*, il vous suffit de vous laisser guider dans la navigation !

**Tout mobile possédant un accès Internet et un navigateur. L'accès au Pré-Congrès 2011 sur terminal mobile (y compris iPhone) nécessite une connexion data pour fonctionner. Si vous vous trouvez à l'étranger, la consultation des données peut engendrer des coûts importants en fonction du type de forfait souscrit avec votre opérateur mobile. Pour utiliser cette application sans passer par votre forfait opérateur mobile, connectez-vous à un hotspot WIFI (en général disponible gratuitement sur tous les salons ou congrès).*

1^{ère} PARTIE

Le programme au jour le jour
et la sélection de notre comité
scientifique

MERCREDI 7 DÉCEMBRE

8:45-9:15

PLENARY LECTURE 1 Exhibit Hall D

Endocrine Therapy for Breast Cancer:
Looking Into the Future ★★★★★
Eric P. Winer

9:15-11:30

GENERAL SESSION 1 Exhibit Hall D

Kathy D. Miller

9:15

S1-1 - A Phase III randomized trial of Anastrozole
versus Anastrozole and Fulvestrant as first-line
therapy for postmenopausal women with
metastatic breast cancer: SWOG S0226 ★
Mehta RS

9:30

S1-2 - Long-term follow-up in ABCSG-12:
Significantly improved overall survival with
adjuvant Zoledronic Acid in premenopausal
patients with endocrine-receptor—positive early
breast cancer ★
Gnant M

9:45

S1-3 - Long-term survival outcomes among
postmenopausal women with hormone
receptor-positive early breast cancer receiving
adjuvant Letrozole and Zoledronic Acid: 5-year
follow-up of ZO-FAST ★
de Boer R

10:00

Discussion
James N. Ingle

10:15

S1-4 - Retrospective analysis of study EGF30008
by mass-spectrometry based serum assay
(VeriStrat®)
Roder J

10:30

S1-5 - Modulation of cancer and stem cell
biomarkers by the notch inhibitor MK-0752
added to endocrine therapy for early stage ER+
breast cancer ★
Albain KS

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

17:00-19:00

PD01-09 - Identifying Novel Mechanisms of Resistance to Lapatinib in ERBB2+ Breast Cancer Cells through Whole Genome Mutational Analysis

Jegg A

POSTER DISCUSSION II Ballroom B

Local Therapy

Richard Crownover & Ismail Jatoi

PD02-01 - Impact of Contralateral Prophylactic Mastectomy on Surgical Outcomes ★

Stover AC

PD02-02 - A Decision Analysis of Contralateral Prophylactic Mastectomy in Women Undergoing Treatment for Sporadic Unilateral Breast Cancer ★

Lester-Coll NH

PD02-03 - The Effect of Breast Conservation Therapy vs Mastectomy on Symptoms, Physical Impairments, and Function

Kesarwala AH

PD02-04 - A Randomized, Prospective, Multicenter Study of the Impact of Intraoperative Margin Assessment with Adjunctive Use of MarginProbe vs. Standard of Care

Schnabel F

PD02-05 - MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial

Mukhtar RA

PD02-06 - Outcomes after Total-Skin Sparing Mastectomy and Immediate Reconstruction in 657 Breasts

Warren Peled A

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

PD02-07 - Models Predicting Non-Sentinel Node Involvement in Breast Cancer Also Predict for Regional Recurrence If the Axilla Is Not Treated

Pepels M



PD02-08 - Validation over Time of a Nomogram Predicting the Sentinel Node Positivity in Early Breast Carcinoma According to the Molecular Subtypes Classification

Ngô C



PD02-09 - RTOG 9804: A Prospective Randomized Trial for «Good Risk» Ductal Carcinoma In Situ (DCIS), Comparing Radiation (RT) to Observation (OBS)

McCormick B



17:00-19:00

POSTER SESSION 1 & RECEPTION Exhibit Hall A-B

Tumor Cell Biology: Immunology and Preclinical Immunotherapy

P1-01-06 - Mechanisms of Tumor Immune Escape in Triplenegative Breast Cancers (TNBC) with and without Mutated BRCA 1

Segerer SE

P1-01-15 - Do Serum Cytokines Predict Breast Cancer Behavior?

Lush E

Tumor Cell Biology: Epithelial-Mesenchymal Transition

P1-02-05 - Invasive Lobular Carcinoma - A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features

Metzger O

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

Tumor Cell Biology: Microenvironment - Stromal-Epithelial Interactions

P1-03-02 - The Norton-Simon Hypothesis and
Cancer Stem Cells: How Cancer Stem Cells
May Explain the Effectiveness of Dose-Dense
Chemotherapy

Landis MD

P1-03-07 - Subtype-Specific Gene Expression
Signatures in Peritumoral Non-Neoplastic Breast
Tissue

Williams T

Tumor Cell Biology: Stem/Progenitor Cells

P1-04-05 - TDM1 and Pertuzumab as New Tools
for HER2 Specific Antibody-Therapy Against
Breast Cancer Stem Cells in HER2-Positive
Mammary Carcinoma

Honig A

P1-04-07 - Poly (ADP-Ribose) Polymerase-1
(PARP-1) Is Overexpressed in Human Breast
Cancer Stem Cells: Results from a Proteomic-
Based Approach

Gilabert M

Prognosis/Response Predictions: Response Predictions - I

P1-06-08 - Effect of Treatment Emergent
Symptoms on Relapse Free Survival: NCIC CTG
MA.12 a Randomized Placebo-Controlled Trial of
Tamoxifen after Adjuvant Chemotherapy in Pre-
Menopausal Women in Early Breast Cancer

Chapman J-AW

P1-06-10 - Lobular Breast Cancer and NAC:
Combined Results from the NKI and I-SPY 1 Trial

Mukhtar RA

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

P1-06-12 - Circulating Tumor Cells (CTC)
Monitoring during Phase II Study with Lapatinib
(L) and Capecitabine (C) in Patients with Brain
Metastases from HER2-Positive (+) Metastatic
Breast Cancer (MBC) before Whole Brain
Radiotherapy (WBR): LANDSCAPE Study

Pierga J-Y

P1-06-16 - BRCA2 Mutation Carriers Respond
Poorly to Conventional Anthracyclins/Taxanes-
Based Neo-Adjuvant Chemotherapy

Raphael J

P1-06-22 - Identification of Biomarkers in Breast
Cancer for Prediction of Response to PARP
Inhibitor Olaparib

Daemen A

P1-06-23 - Changes in Gene Expression after One
Dose of Trastuzumab (T) in HER2+ Breast Cancer
Cell Lines Predict Novel Pathways of Response in
HER2 Positive Early Stage Breast Cancer

Sprecher E

Prognosis/Response Predictions:
Biomarkers - Methods

P1-07-10 - Validation of a Diagnostic Molecular
Signature (EHT Dx14) on Fine-Needle Aspirate
Samples from Breast Tumors

Delaloge S

P1-07-20 - Consistent High False Negative
Rate of HER2 qRT-PCR of Oncotype DX® in
Comparison to ASCO/CAP Recommended
Combined IHC/FISH Method

Dabbs DJ

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

Epidemiology, Risk, and Prevention:
Epidemiology - Population Studies

P1-08-01 - Survival in Metastatic Breast Cancer
(MBC): No Evidence for Improved Survival
Following Distant Recurrence after Adjuvant
Chemotherapy

Tevaarwerk AJ

P1-08-07 - Survival in US Women Following
an Indication of Metastatic Breast Cancer
Diagnosis and Chemotherapy Initiation: A SEER-
Medicare Analysis

Rugo H

P1-08-17 - Pregnancy-Associated Breast Cancer
Does Not Have a Worse Outcome in the 4912
Women with Breast Cancer of the AMAZONA
Project

Liedke PER

P1-08-23 - Characteristics of De Novo Stage IV
Breast Cancer Presentation and Comparison
with Stage IV Disease Relapse after Adjuvant
Therapy

Chen L

Psychosocial, Quality of Life, and
Educational Aspects: Cost-Effectiveness

P1-10-02 - Burden of Brain Metastases in
HER2-Positive Breast Cancer: Healthcare
Use and Costs from a French Observational
Retrospective Multicenter Study

Baffert S

P1-10-06 - Economic Analysis of Chemotherapy
Costs for Adjuvant Therapy in Breast Cancer in
France

Chereau E

MERCREDI 7 DÉCEMBRE

MERCREDI 7 DÉCEMBRE

Treatment - Therapeutic Strategies: HER2-Targeted Therapy

P1-12-01 - Pregnancy during and Following Adjuvant Trastuzumab in Patients with HER2-Positive Breast Cancer: An Analysis from the HERA Trial (BIG 01-01)

Azim, Jr

P1-12-05 - Complete Pathological Response of Ductal Carcinoma In Situ after Treatment with Neoadjuvant Herceptin

Chalmers CR

P1-12-11 - Neoadjuvant Chemotherapy-Trastuzumab Versus Neoadjuvant Chemotherapy Followed by Post-Operative Trastuzumab: A Multicentre Study

Palmieri C

P1-12-15 - Adjuvant Trastuzumab Effect on HER2-Positive Breast Cancers According to Hormonal Receptor (HR) Status: Crosstalk between ER and EGFR/HER2 Pathway May Prevent Trastuzumab from Improving Outcomes in HER2-Positive and HR-Positive Breast Cancers

Park YH

P1-12-21 - Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer

Dall P

P1-12-24 - Adherence and Persistence with Lapatinib in Women with Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab

Delea TE

MERCREDI 7 DÉCEMBRE

JEUDI 8 DÉCEMBRE

07:00-09:00

POSTER SESSION 2 & BREAKFAST Exhibit Hall A-B

Tumor Cell Biology: Tumor Progression,
Invasion, and Metastasis

P2-01-04 - The Post-Partum Diagnosis of
Pregnancy Associated Breast Cancer Confers an
Increased Risk for Metastasis without Increased
Incidence of Poorer Prognosis Biologic Subtype

Borges VF

P2-01-24 - Triple-Negative Breast Cancer
Emerges from the Luminal Progenitor
Compartment

Nogi H

Detection and Diagnosis - Imaging and
Screening: Breast Imaging - MRI

P2-08-12 - Additional Lesion Found in
Preoperative Breast MRI; Is Routine Use
Justified?

Kim J

P2-08-13 - Does Routine Use of Preoperative
Magnetic Resonance Imaging (MRI) in Breast
Cancer Influence the Outcome?

Große R

Detection and Diagnosis - Imaging and
Screening: Molecular, Functional, and Novel
Imaging

P2-09-02 - Predicting Response to Bevacizumab
in Primary Breast Cancer Using 18F-
Fluorothymidina (FLT) and 18F-Misonidazole
(MISO) Positron Emission/Computed
Tomography (PET/CT) as Imaging Biomarkers

Dominguez I

JEUDI 8 DÉCEMBRE

JEUDI 8 DÉCEMBRE

P2-18-03 - Systemic Adjuvant Treatment of T1a and T1b N0M0 HER2+ Breast Carcinomas; an AERIO/UNICANCER Study

Peron J

Treatment - Adjuvant: Adjuvant Therapy - Other

P2-19-02 - Multidisciplinary Treatment of Pregnancy-Associated Breast Cancer

Meisel JL

07:00-09:00

POSTER DISCUSSION III Ballroom A

Genomics

Laura J. van't Veer

PD03-01 - An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC

Van Laere SJ

PD03-02 - Prognostic and Predictive Predictors for Triple Negative Breast Cancer ★★

Karn T

PD03-03 - Identification of Transcription Factors Critical for the Growth of Basal Breast Cancer

Shepherd JH

PD03-04 - SuperPathway Analyses of Luminal and Basaloid Breast Cancers from the Cancer Genome Atlas (TCGA) Program

Yau C

PD03-05 - Withdrawn

PD03-06 - Basal-Like Breast Tumors Are Associated with Frequent Micro Genomic Aberrations in Important Cancer Genes

Chao H-H

JEUDI 8 DÉCEMBRE

JEUDI 8 DÉCEMBRE

PD03-07 - Breast Cancer Heterogeneity and Treatment Resistance: Clues from Metaplastic Tumors ★

Felding-Habermann B

PD03-08 - BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents ★★

Wesseling J

PD03-09 - Breast Cancer Recurrence Risk Probed by Whole Transcriptome Next Generation Sequencing in 136 Patients

Baker J

PD03-10 - Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis ★★

Ignatiadis M

07:00-09:00

POSTER DISCUSSION IV Ballroom B

Survivorship

Dawn Hershman

PD04-01 - Predictors of Recovery of Ovarian Function during Aromatase Inhibitor (AI) Therapy ★

Henry NL

PD04-02 - Recovery of Ovarian Function in Breast Cancer Patients with Chemotherapy-Induced Amenorrhea Receiving Anastrozole in the Dutch DATA Study ★

Tjan-Heijnen VC

PD04-03 - Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity

Goldfarb SB

JEUDI 8 DÉCEMBRE

JEUDI 8 DÉCEMBRE

P3-14-14 - Increased Prevalence of Low Vitamin D Level in Breast Cancer Patients during Neoadjuvant Chemotherapy

Jacot W

P3-14-22 - Response to Neoadjuvant Chemotherapy in Elderly Patients with Locally Advanced Breast Cancer

Vanderhaegen J

P3-14-25 - Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity

Dolcetti R

P3-14-31 - Preoperative Chemotherapy and Bevacizumab for Locally Advanced HER-2 Negative Breast Cancer Followed by Prolonged Postoperative Bevacizumab for Those with Less Than Complete Pathologic Response

Carpenter JT

Treatment - Therapeutic Strategies: New Drugs and Treatment Strategies

P3-16-08 - A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC

Hawse JR

P3-16-10 - The Efficacy of Zoledronic Acid in Breast Cancer Adjuvant Therapy: A Meta-Analysis of Randomized Controlled Trials

Lu J

Treatment - Therapeutic Strategies: Signal Transduction Inhibitors

P3-18-04 - Pathway Guided Selection of Targeted Inhibitors for Breast Cancer Treatment

von Ahsen O

JEUDI 8 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

Detection and Diagnosis - Pathology: Circulating Markers

P4-08-01 - Predictive Value of HER2 Serum
Levels in Patients Treated with Lapatinib or
Trastuzumab - A Translational Project in the
Neoadjuvant «Geparquinto» Trial

Witzel ID

Prognosis/Response Predictions: Prognostic Factors and Biomarkers - Clinical - II

P4-09-01 - Identification of Poor Prognosis
T1T2N0 Luminal ERBB2-ve Breast Carcinomas

Vincent-Salomon A

P4-09-03 - Clinical Significance of HER2+ and
Triple-Negative Status in Patients with Tumor
Size ≤ 1 cm and Node Negative Breast Cancer

Shao T

P4-09-10 - Assessment of Circulating Immune
Parameters in Patients with Metastatic Breast
Cancer Improves Survival Prediction

Tredan O

P4-09-22 - Multicenter Quality Assurance Profile
Review of Lobular Breast Carcinomas Versus
the 21 Gene Recurrence Score: Assessment of
Clinical Relevance

Dabbs DJ

Treatment - Types and Sites of Breast Cancer: Brain Metastases

P4-17-01 - Trastuzumab Does Not Increase the
Incidence of Central Nervous System (CNS)
Relapses in HER2-Positive Early Breast Cancer:
The HERA Trial Experience

Pestalozzi B

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

P4-17-02 - Whole-Brain Radiation Therapy Plus
Concomitant Temozolomide for the Treatment
of Brain Metastases from Breast Cancer: A
Randomized Prospective Multicenter Phase II
Study

Kirova YM

P4-17-03 - Incidence Rate of Asymptomatic
Brain Metastases in Patients with HER2+
Metastatic Breast Cancer Screened for
EGF111438/CEREBEL Study

Pivot X

Treatment - Types and Sites of Breast
Cancer: DCIS/LCIS

P4-18-03 - Basal-Like Phenotype of BRCA
Associated Ductal Carcinoma *In-Situ*

Kristjansdottir K

Treatment - Types and Sites of Breast
Cancer: Inflammatory Breast Cancer

P4-20-01 - Multicentric Phase II PACS 09/
Beverly1 Trial: First Efficacy and Safety Results
of Neoadjuvant Chemotherapy Combined with
Bevacizumab in HER2-Negative Patients with
Non-Metastatic Inflammatory Breast Cancer

Viens P

07:00-09:00

POSTER DISCUSSION VII Ballroom A

What's New In Chemotherapy Trials?

Clifford Hudis

PD07-01 - Sequential Treatment with Epirubicin/
Cyclophosphamide, Followed by Docetaxel vs.
FEC120 in the Adjuvant Treatment of Breast
Cancer Patients with Extensive Lymph Node
Involvement: Final Survival Analysis of the
German ADEBAR Phase III Study ★★

Janni WJ

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

PD07-02 - Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan



Watanabe T

PD07-03 - Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HERTC) in HER2-Positive Early Stage Breast Cancer Patients



Jones S

PD07-04 - Lapatinib vs Trastuzumab in Combination with Standard EC-D Chemotherapy in the Neoadjuvant Treatment of HER2+ Patients. Results from the GEICAM 2006-14 Phase II Randomized Trial



Alba E

PD07-05 - Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/- Trastuzumab Containing Chemotherapy



von Minckwitz G

PD07-06 - Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial



Nitz U

PD07-07 - Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG)



Lam SW

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

PD07-08 - The Effect on Surgical Complications
of Bevacizumab Added to Neoadjuvant
Chemotherapy: NSABP Protocol B-40 ★

Bear HD

07:00-09:00

POSTER DISCUSSION VIII Ballroom B

Targeting Triple Negatives and Stem Cells

Geoffrey Lindeman

PD08-01 - JNK2 Regulates Mammary Lineage
Differentiation in Tumors and Normal Glands
through Notch1 and p53

Cantrell MA

PD08-02 - Targeting BCL2 Expressing Breast
Tumors with BH3-Mimetics - A New Class of
Drugs in Breast Cancer?

Lindeman GJ

PD08-03 - Inhibition of MEK/ERK- and JNK-
Dependent Expression of Interleukin-6 and
Interleukin-8 Targets Basal-Like Breast Cancer
Stem Cells

Balko JM

PD08-04 - Inhibition of the TGF_β/TGF_βR2
Pathway Prevents Enrichment of Drug-Resistant
Breast Cancer Stem Cells by Anti-Cancer
Chemotherapy

Bhola N

PD08-05 - Stat3 Signaling in Human Breast
Cancer Stem Cells

Wei W

PD08-06 - ERK2 Promotes Stem Cell-Like
Characteristics in Triple-Negative Breast Cancer

Bartholomeusz C

PD08-07 - Wound-Healing Drainage Fluids
Promote Triple Negative Breast Cancer
Progression ★

Campiglio M

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

PD08-08 - Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer

Gartner EM

PD08-09 - PTPN12 Gene Expression Signature in Triple Negative Breast Cancer Cohort

Ghazalpour A

PD08-10 - High Frequency of Triple Negative Mammary Carcinomas in the Dog as Model of Human Breast Cancer

Nguyen F

PD08-11 - Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer

Liu J

09:00-09:30

PLENARY LECTURE 3 Exhibit Hall D

Advances in Axillary Surgery: Sentinel Nodes and Beyond



L. Smith, MD, PhD

09:30-11:30

GENERAL SESSION 5 Exhibit Hall D

Mothaffar Rimawi, MD

09:30

S5-1 - Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC)



Gianni L

09:45

S5-2 - PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/Taxane and Trastuzumab/Taxane containing regimens in HER2-positive breast cancer



Cheang M

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

11:30-12:00

**AACR Outstanding Investigator
Award for Breast Cancer
Research, funded by Susan G.
Komen for the Cure®
Exhibit Hall D**

Alteration and Inhibition of PTEN in Breast
Cancer 

Ramon E. Parsons

12:30-13:35

**CASE DISCUSSION 2
Ballroom A**

12:30-13:35

**BASIC SCIENCE FORUM
Ballroom B**

Tumor Microenvironment

Rong Li, PhD

12:30-13:35

Forcing breast cancer risk & progression

Valerie M. Weaver

12:30-13:35

COX-2 dependent collagen fibrillogenesis
drives metastasis in the postpartum involuting
mammary gland

Pepper J. Schedin

13:45-15:15

**MINI-SYMPOSIUM 3
Ballroom B**

Metabolism in Breast Cancer -
Metabolomics

Michael Pollak

13:45-15:15

Adiposity, metabolism, and risk of breast cancer

Susan E 

13:45-15:15

HIF-1, metabolism, and metastasis

Gregg L 

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

PD09-04 - A Phase Ib, Open-Label,
Dose-Escalation Study of the Safety and
Pharmacology of the PI3-Kinase Inhibitor
GDC-0941 in Combination with Paclitaxel and
Bevacizumab in Patients with Locally Recurrent
or Metastatic Breast Cancer ★

Schöffski P

PD09-05 - SU2C Phase Ib Study of pan-PI3K
Inhibitor BKM120 Plus Aromatase Inhibitor
Letrozole in ER+/HER2- Metastatic Breast
Cancer (MBC) ★

Mayer IA

PD09-06 - Phase II Trial of RAD001 (Everolimus),
an mTOR Inhibitor, with Weekly Cisplatin and
Paclitaxel in Patients with HER2-Negative
Metastatic Breast Cancer (MBC) ★

Mayer IA

PD09-08 - Combined Inhibition of mTORC1 with
Temsirolimus and HER2 with Neratinib: A Phase
I/II Study in Patients with Metastatic HER2-
Amplified or Triple-Negative Breast Cancer ★

Gajria D

17:00-19:00

POSTER DISCUSSION X Ballroom B

Tumor Suppressors/DNA Repair

Nicholas Turner

PD10-01 - Prevalence of Dysfunctional Fanconi
Anemia (FA) DNA Repair Pathway in Breast
Cancer

Ramaswamy B

PD10-02 - Sporadic Breast Cancers Show
Defects in the BRCA1-BRCA2 Pathway of
Homologous Recombination in All Biomarker-
Defined Sub-Types of Breast Cancer

Powell SN

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

PD10-03 - Withdrawn

PD10-04 - Exploration of the Relationship
between Loss of PTEN and BRCA1 Expression
in Triple Negative Breast Carcinoma

Jones N

PD10-05 - Identification of Novel BRCA1
Transcriptional Targets That Promote the Survival
of BRCA1-Mutated Estrogen Receptor- α
Negative (ER-ve) Breast Tumours

Lamers E

PD10-06 - Loss of the Retinoblastoma Tumor
Suppressor (RB) in Triple Negative Breast Cancer
Is Associated with a Favorable Prognosis

Witkiewicz AK

PD10-07 - microRNA Profiles of Breast Tumors
Identifies the miR 17-92 Cluster as a Group of
Potentially Essential Oncomirs in Triple-Negative
Breast Cancer

Son BH

17:00-19:00

POSTER SESSION 5 & RECEPTION Exhibit Hall A-B

Tumor Cell Biology: Biomarkers

P5-01-11 - Small Node-Negative (T1b-cN0)
Invasive Hormone Receptor (HR)-Positive Breast
Cancers: Is There a Population Which Might
Have Benefit from Adjuvant Chemotherapy?

Park YH

Tumor Cell Biology: Etiology/Carcinogenesis

P5-05-03 - The Effect of Breastfeeding on
Molecular Characteristics of Invasive Breast
Cancer

Ellsworth RE

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

Detection and Diagnosis: Imaging and Screening: Radiology - Tumor Monitoring

P5-10-01 - Metabolic Pharmacodynamic Effect
Evidenced by 18FDG-PET as a Tool for Early
Prediction of Iniparib Efficacy in Metastatic Triple
Negative Breast Cancer (MTNBC): A Proof of
Concept Study

Kerrou K

Prognosis/Response Predictions: Response Predictions - II

P5-13-07 - MET and Hepatocyte Growth
Factor (HGF) Increased Gene Copy Number
Is Associated to Trastuzumab Failure in HER2
Positive Metastatic Breast Cancer (MBC)

Minuti G

Prognosis/Response Predictions: Prognostic and Predictive Factors - Other

P5-14-01 - Differences in Efficacy by
Assessment Method: NCIC CTG Adjuvant
Breast Cancer Trials MA.5, MA.12, MA.14,
MA.21, MA.27 Meta-Analysis

Dong B

P5-14-15 - Prognostic Impact of Chemotherapy-
Induced Amenorrhea (CIA) in Premenopausal
Breast Cancer: A Meta-Analysis of Published
Literatures

Lu J

P5-14-20 - Neoadjuvant Chemotherapy (NCT) in
466 Patients for Operable Breast Cancer: The
Prognostic Value of SBR Grade Variation

Abrial C

VENDREDI 9 DÉCEMBRE

VENDREDI 9 DÉCEMBRE

Treatment - Chemotherapy: Adjuvant Chemotherapy

P5-18-04 - Safety Profile of Ixabepilone as
Adjuvant Treatment for Poor Prognosis Early
Breast Cancer: First Results of the Unicancer-
PACS 08 Trial

Campane M

P5-18-13 - Adjuvant Chemotherapy with
Vinorelbine+5FU or Capecitabine in Poor
Responders to Neoadjuvant EC- Docetaxel
Chemotherapy (NAC) for Locally Advanced
Breast Cancers

Giacchetti SSG

Treatment - Chemotherapy: Chemotherapy in Advanced Disease

P5-19-01 - Final Results of a Three-Arm
Randomised Phase II Study of Oral Vinorelbine
Plus Capecitabine Versus Oral Vinorelbine and
Capecitabine in Sequence *Versus* Docetaxel
Plus Capecitabine in Patients with Metastatic
Breast Cancer Previously Treated with
Anthracyclines

Campane M

P5-19-04 - Results of a Randomized Phase II
Study Demonstrate Benefit of Platinum-Based
Regimen in the First-Line Treatment of Triple
Negative Breast Cancer (TNBC)

Fan Y

Treatment - Chemotherapy: Toxicities and Management

P5-20-06 - Survival in Women with Breast
Cancer Who Used or Did Not Use Scalp Cooling
in the Neoadjuvant/Adjuvant Setting

Lemieux J

VENDREDI 9 DÉCEMBRE

SAMEDI 10 DÉCEMBRE

08:00-10:00

SPECIAL REPORT **Exhibit Hall D**

Genome Data for the Masses: Presentation
of TCGA and IGC Breast Tumor Data

Charles M. Perou ; Michael Stratton

TCGA breast cancer sequencing: Results and
interpretation

Mardis ER

Diverse patterns of mutation in breast cancer
genomes

Stratton M

Integrative genomic analyses of breast cancer
from The Cancer Genome Atlas (TCGA)

Creighton CJ

Epigenomic data analysis of TCGA breast cancer
samples

Laird PW

The DNA copy number landscapes and genomic
architecture: Relevance for progression and
outcome

Børresen-Dale AL

Genomic analyzes for pathway characterization

Haussler D

10:00-12:00

THE YEAR IN REVIEW **Exhibit Hall D**

Advances in basic breast cancer research

Kornelia Polyak

Translational breast cancer research

Andrea Richardson

Early breast cancer

Nancy E. Davidson

SAMEDI 10 DÉCEMBRE

SAMEDI 10 DÉCEMBRE

Challenges and success: Treatment of
metastatic breast cancer 2011

Hope S. Rugo

2^{ème} PARTIE

Les sessions cotées ★★★

Les sessions cotées ★★

LA SÉLECTION ★★★

MERCREDI 7 DÉCEMBRE

- 8:45-9:15 **PLENARY LECTURE 1**
Exhibit Hall D
Endocrine Therapy for Breast Cancer:
Looking Into the Future ★★★
Eric P. Winer
- 11:30 -12:00 **ACR DISTINGUISHED**
LECTURESHIP IN BREAST
CANCER RESEARCH
Exhibit Hall D
Protective Adaptive Responses to Breast
Cancer Therapies ★★★
Joan S
- 14:15-16:00 **GENERAL SESSION 2**
Exhibit Hall D Julie R. Gralow
- 14:15 S2-1 - Partial breast brachytherapy is associated
with inferior effectiveness and increased toxicity
compared with whole breast irradiation in older
patients ★★★
Smith GL
- 14:45 S2-3 - NSABP protocol B-34: A clinical trial
comparing adjuvant Clodronate vs. placebo in
early stage breast cancer patients receiving
systemic chemotherapy and/or Tamoxifen or no
therapy - final analysis ★★★
Paterson AHG

LA SÉLECTION ★★★

- 16:00-17:00 **SUSAN G. KOMEN FOR THE**
CURE BRINKER AWARDS
FOR SCIENTIFIC DISTINCTION
LECTURES
Exhibit Hall D
- 16:00-17:00 Oncogene & ER: A convenient marriage for
hormone-dependant breast cancer ★★★
Carlos L. Arteaga
- 16:00-17:00 Changes in the management of the Axilla in
Breast Cancer ★★★
Armando E. Giuliano
- 17:00-19:00 **POSTER DISCUSSION II**
Ballroom B
Local Therapy
Richard Crownover & Ismail Jatoi
- 17:00-19:00 PD02-09 - RTOG 9804: A Prospective
Randomized Trial for «Good Risk» Ductal
Carcinoma In Situ (DCIS), Comparing Radiation
(RT) to Observation (OBS) ★★★
McCormick B

JEUDI 8 DÉCEMBRE

- 09:00-09:30 **GENERAL SESSION 3**
Exhibit Hall D Jose Baselga
- 09:00-09:30 S3-1 - Update of international breast cancer
study group trial 23-01 to compare axillary
dissection *versus* no axillary dissection in
patients with clinically node negative breast
cancer and micrometastases in the sentinel
node ★★★
Galimberti V

LA SÉLECTION ★★★
JEUDI 8 DÉCEMBRE 2011

- 09:45 S3-2 - Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial ★★★
von Minckwitz G
- 10:45 S3-6 - Neoadjuvant chemotherapy of Paclitaxel with or without Rad001: Results of the non-responder part of the GEPARQUINTO study (GBG 44) ★★★
Huober J
- 15:15-17:15 **GENERAL SESSION 4**
Exhibit Hall D Emiel JT Rutgers
- 15:45 S4-3 - Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-Plan B trial ★★★
Gluz O
- 16:15 S4-5 - Comparison of PAM50 risk of recurrence (ROR) score with oncotypeDx and IHC4 for predicting residual risk of RFS and distant-(D) RFS after endocrine therapy: A TransATAC study ★★★
Dowsett M
- 16:45 S4-7 - Results of a randomized, double-blind, multicenter, placebo-controlled study of adjuvant lapatinib in women with early-stage ErbB2-overexpressing breast cancer ★★★
Goss P
- 17:00 S4-8 - First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) ★★★
Gianni L

LA SÉLECTION ★★★

VENDREDI 9 DÉCEMBRE

- 09:30-11:30 **GENERAL SESSION 5**
Exhibit Hall D Mothaffar Rimawi, MD
- 09:30 S5-1 - Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC) ★★★
Gianni L
- 10:15 S5-4 - pCR as a surrogate in HER2-positive patients treated with Trastuzumab ★★★
Loibl S
- 10:30 S5-5 - A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel vs. placebo + Trastuzumab + Docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA) ★★★
Baselga J

LA SÉLECTION ★★

MERCREDI 7 DÉCEMBRE

- 9:15-11:30 **GENERAL SESSION 1**
Exhibit Hall D Kathy D. Miller
- 10:45 S6-1 - Characterization of breast cancer distant metastasis based on outcome over time using a gene expression profiling approach and identification of pathway activities of late relapse
Saghatchian M ★★
- 12:30-13:35 **BASIC SCIENCE FORUM**
Ballroom B
- 14:30 S2-2 - Luminal A subtype predicts radiation response in patients with T1N0 breast cancer enrolled in a randomized trial of Tamoxifen with or without breast radiation
Fyles A ★★
- 15:00 S2-4 - Gain (German Adjuvant Intergroup Node Positive) study: A phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim EFFICACY analysis
Möbus V ★★
- 17:00-19:00 **POSTER DISCUSSION II**
Ballroom B
- Local Therapy
Richard Crownover & Ismail Jatoi
- 17:00-19:00 PD02-08 - Validation over Time of a Nomogram Predicting the Sentinel Node Positivity in Early Breast Carcinoma According to the Molecular Subtypes Classification
Ngô C ★★

LA SÉLECTION ★★

JEUDI 8 DÉCEMBRE

- 07:00-09:00 **POSTER DISCUSSION III**
Ballroom A
- Genomics
Laura J. van't Veer
- 07:00-09:00 PD03-02 - Prognostic and Predictive Predictors for Triple Negative Breast Cancer
Karn T ★★
- 07:00-09:00 PD03-08 - BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents
Wesseling J ★★
- 07:00-09:00 PD03-10 - Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
Ignatiadis M ★★
- 09:00-09:30 **GENERAL SESSION 3**
Exhibit Hall D Jose Baselga
- 10:30 S3-5 - Next generation sequencing reveals co-activating events in the MAPK and P13K/AKT pathways in metastatic triple negative breast cancers
O'Shaughnessy J ★★
- 15:15-17:15 **GENERAL SESSION 4**
Exhibit Hall D Emiel JT Rutgers
- 15:15 S4-1 - Overdiagnosis in breast cancer screening: Methodological considerations of current estimates
Smith RA ★★

LA SÉLECTION ★★
JEUDI 8 DÉCEMBRE 2011

- 16:30 S4-6 - A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194 ★★
Solin LJ
- 17:15-19:00 **POSTER DISCUSSION V**
Ballroom A
HER2
Michael F. Press
- 17:15-19:00 PD05-01 -Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer ★★
Guarneri V
- 17:15-19:00 PD05-02 - Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel - A Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials ★★
Dafni U
- 17:15-19:00 PD05-05 - Meta Analysis of Discordant HER2 Status in Matched Primary and Metastatic Breast Cancer ★★
Richter S
- 17:15-19:00 PD05-07 - Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer ★★
Olson EM

LA SÉLECTION ★★

VENDREDI 9 DÉCEMBRE

- 07:00-09:00 **POSTER DISCUSSION VII**
Ballroom A
What's New In Chemotherapy Trials?
Clifford Hudis
- 07:00-09:00 PD07-01 - Sequential Treatment with Epirubicin/ Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study ★★
Janni WJ
- 07:00-09:00 PD07-04 - Lapatinib vs Trastuzumab in Combination with Standard EC-D Chemotherapy in the Neoadjuvant Treatment of HER2+ Patients. Results from the GEICAM 2006-14 Phase II Randomized Trial ★★
Alba E
- 07:00-09:00 PD07-07 - Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/ MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG) ★★
Lam SW
- 09:00-09:30 **PLENARY LECTURE 3**
Exhibit Hall D
Advances in Axillary Surgery: Sentinel Nodes and Beyond ★★
L. Smith, MD, PhD

LA SÉLECTION ★★

VENDREDI 9 DÉCEMBRE 2011

- 09:30-11:30 **GENERAL SESSION 5**
Exhibit Hall D Mothaffar Rimawi, MD
- 09:45 S5-2 - PAM50 HER2-enriched subtype
enriches for tumor response to neoadjuvant
anthracyclines/Taxane and Trastuzumab/Taxane
containing regimens in HER2-positive breast
cancer ★★
Cheang M
- 10:45 S5-6 - Neoadjuvant Pertuzumab and Trastuzumab
concurrent or sequential with an Anthracycline-
containing or concurrent with an Anthracycline-
free standard regimen: A randomized phase II
Study (TRYPHAENA) ★★
Schneeweiss A
- 11:00 S5-7 - A phase 2, randomized, open-label,
study of Neratinib (HKI-272) vs Lapatinib plus
Capecitabine for 2nd/3rd-line treatment of
HER2+ locally advanced or metastatic breast
cancer ★★
Martin M
- 11:30-12:00 **AACR Outstanding Investigator**
Award for Breast Cancer
Research, funded by Susan G.
Komen for the Cure®
Exhibit Hall D
- Alteration and Inhibition of PTEN in Breast
Cancer ★★
Ramon E. Parsons
- 15:15 **GENERAL SESSION 6**
Exhibit Hall D Pamela Goodwin
- 16:15 S6-4 - Protein kinase mutation patterns in human
breast ★★
Pusztai L

LA SÉLECTION ★★

VENDREDI 9 DÉCEMBRE 2011

- 17:00-19:00 **POSTER DISCUSSION IX**
Ballroom A
- PI3K / mTOR
Ana-Maria Gonzalez-Angulo
- 17:00-19:00 PD09-01 - Target-Based Therapeutic Matching
in Early-Phase Clinical Trials in Patients with
Advanced Breast Cancer and PIK3CA Mutations
Janku F ★★

MARDI
6 DÉCEMBRE

7H00.....
.....
8H00.....
.....
9H00.....
.....
10H00.....
.....
11H00.....
.....
12H00.....
.....
13H00.....
.....
14H00.....
.....
15H00.....
.....
16H00.....
.....
17H00.....
.....
18H00.....
.....
19H00.....
.....
20H00.....
.....

MERCREDI
7 DÉCEMBRE

7H00.....
.....
8H00.....
.....
9H00.....
.....
10H00.....
.....
11H00.....
.....
12H00.....
.....
13H00.....
.....
14H00.....
.....
15H00.....
.....
16H00.....
.....
17H00.....
.....
18H00.....
.....
19H00.....
.....
20H00.....
.....

JEUDI
8 DÉCEMBRE

7H00.....
.....
8H00.....
.....
9H00.....
.....
10H00.....
.....
11H00.....
.....
12H00.....
.....
13H00.....
.....
14H00.....
.....
15H00.....
.....
16H00.....
.....
17H00.....
.....
18H00.....
.....
19H00.....
.....
20H00.....
.....

VENDREDI
9 DÉCEMBRE

7H00.....
.....
8H00.....
.....
9H00.....
.....
10H00.....
.....
11H00.....
.....
12H00.....
.....
13H00.....
.....
14H00.....
.....
15H00.....
.....
16H00.....
.....
17H00.....
.....
18H00.....
.....
19H00.....
.....
20H00.....
.....

SAMEDI
10 DÉCEMBRE

7H00.....
.....
8H00.....
.....
9H00.....
.....
10H00.....
.....
11H00.....
.....
12H00.....
.....
13H00.....
.....
14H00.....
.....
15H00.....
.....
16H00.....
.....
17H00.....
.....
18H00.....
.....
19H00.....
.....
20H00.....
.....

TÉLÉCHARGEZ L'APPLICATION PUBLICLIN PRÉ-CONGRÈS sur votre mobile :

TOUT LE PRÉ-CONGRÈS DU
SABCS 2011 À PORTÉE DE MAIN !

DÉTAILS À L'INTÉRIEUR



Une édition

PubliClin'

avec le soutien institutionnel de

